About gastrointestinal OTC drugs OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country. Technavio's analysts forecast the global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% over the period 2014-2019. Covered in this report This report covers the present scenario and the growth prospects of the global gastrointestinal OTC drugs market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various OTC drugs available in the market for the... Research Beam Model: Research Beam Product ID: 222297 2500 USD New
Global Gastrointestinal OTC Drugs Market 2015-2019
 
 

Global Gastrointestinal OTC Drugs Market 2015-2019

  • Category : Pharmaceuticals
  • Published On : April   2015
  • Pages : 101
  • Publisher : Technavio
 
 
 
About gastrointestinal OTC drugs
OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country.
Technavio's analysts forecast the global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global gastrointestinal OTC drugs market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various OTC drugs available in the market for the management of gastrointestinal disorders such as:
• GERD/Heartburn
• Constipation
• Diarrhea
• Nausea due to motion sickness
• Flatulence
The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also discusses the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
Technavio's report, Global Gastrointestinal OTC Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and EMEA and APAC; it also covers the global gastrointestinal OTC drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Bayer
• GlaxoSmithKline
• Johnson and Johnson
• Perrigo
• Pfizer
• Procter and Gamble
Other prominent vendors

• Abbott
• Boehringer Ingelheim
• C.B. Fleet
• Nestle
• Omega
• Purdue Pharma
• Reckitt Benckiser
• Sanofi
• Teva Pharmaceutical
Market driver
• Increase in patient population
• For a full, detailed list, view our report
Market challenge
• High spending on advertisement
• For a full, detailed list, view our report
Market trend
• Strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market overview
03.2 Product offerings
04. Market Research Methodology
04.1 Market research process
04.2 Research methodology
05. Introduction
06. Overview: OTC Drugs
06.1 Regulatory pathways for OTC approval
06.2 FDA OTC drug approval process
06.2.1 OTC NDA
06.2.2 OTC drug monograph
06.2.3 Gastrointestinal prescription to OTC switch
07. Epidemiology of Gastrointestinal Disorders
08. Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 Top predictions
08.4 Five forces analysis
09. Market Segmentation by Therapeutic Class of Drug
09.1.1 Gastric acid reducers
09.1.2 Gastric acid neutralizers
09.1.3 Laxatives
09.1.4 Antidiarrheals
09.1.5 Antiemetics
09.1.6 Others
10. Market Segmentation by Indication
10.1.1 GERD
10.1.2 Constipation
10.1.3 Diarrhea
10.1.4 Nausea caused by motion sickness
10.1.5 Flatulence
11. Geographical Segmentation
11.1 Gastrointestinal OTC drugs market in Americas
11.1.1 Market size and forecast
11.2 Gastrointestinal OTC drugs market in EMEA
11.2.1 Market size and forecast
11.3 Gastrointestinal OTC drugs market in APAC
11.3.1 Market size and forecast
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive scenario
19.1.1 Key news
19.1.2 Mergers and acquisitions
19.2 Market share analysis 2014
19.2.1 Bayer
19.2.2 GlaxoSmithKline
19.2.3 Johnson and Johnson
19.2.4 Perrigo
19.2.5 Pfizer
19.2.6 PandG
19.3 Other prominent vendors
20. Key Vendor Analysis
20.1 Bayer
20.1.1 Key facts
20.1.2 Business overview
20.1.3 Business segmentation by revenue 2014
20.1.4 Business segmentation by revenue 2013 and 2014
20.1.5 Geographical segmentation by revenue 2014
20.1.6 Business strategy
20.1.7 Recent developments
20.1.8 SWOT analysis
20.2 GlaxoSmithKline
20.2.1 Key facts
20.2.2 Business overview
20.2.3 Business segmentation by revenue 2014
20.2.4 Business segmentation by revenue 2013 and 2014
20.2.5 Geographical segmentation by revenue 2014
20.2.6 Business strategy
20.2.7 Recent developments
20.2.8 SWOT analysis
20.3 Johnson and Johnson
20.3.1 Key facts
20.3.2 Business overview
20.3.3 Business segmentation by revenue 2014
20.3.4 Business segmentation by revenue 2013 and 2014
20.3.5 Geographical segmentation by revenue 2014
20.3.6 Business strategy
20.3.7 Recent developments
20.3.8 SWOT analysis
20.4 Perrigo
20.4.1 Key facts
20.4.2 Business overview
20.4.3 Business segmentation by revenue 2014
20.4.4 Business segmentation by revenue 2013 and 2014
20.4.5 Geographical segmentation by revenue 2014
20.4.6 Business strategy
20.4.7 Recent developments
20.4.8 SWOT analysis
20.5 Pfizer
20.5.1 Key facts
20.5.2 Business overview
20.5.3 Business segmentation by revenue 2014
20.5.4 Business segmentation by revenue 2013 and 2014
20.5.5 Geographical segmentation by revenue 2014
20.5.6 Business strategy
20.5.7 Key developments
20.5.8 SWOT analysis
20.6 PandG
20.6.1 Key facts
20.6.2 Business overview
20.6.3 Business segmentation by revenue 2014
20.6.4 Business segmentation by revenue 2013 and 2014
20.6.5 Geographical segmentation by revenue 2014
20.6.6 Business strategy
20.6.7 Recent developments
20.6.8 SWOT analysis
21. Other Reports in this Series

List of Exhibits:
Exhibit 1: Market research methodology
Exhibit 2: Comparison between prescription and OTC drugs
Exhibit 3: Advantages and disadvantages of OTC drugs
Exhibit 4: Ways to establish an OTC drug in different markets
Exhibit 5: Key regulatory bodies for OTC approval
Exhibit 6: FDA OTC drug approval process
Exhibit 7: Comparison of NDA versus OTC monograph process
Exhibit 8: Mechanisms to amend an OTC drug monograph
Exhibit 9: Drugs underwent Rx-to-OTC switch in US
Exhibit 10: Global gastrointestinal OTC drugs market 2014-2019 ($ million)
Exhibit 11: Top predictions in global gastrointestinal OTC drugs market
Exhibit 13: Global gastrointestinal OTC drugs market by therapeutic class of drug
Exhibit 14: Global gastrointestinal OTC drugs market by therapeutic class of drug 2014
Exhibit 15: Global gastrointestinal OTC drugs market by indication
Exhibit 16: Segmentation of global gastrointestinal OTC drugs market by geography 2014
Exhibit 17: Segmentation of global gastrointestinal OTC drugs market by geography 2019
Exhibit 18: Gastrointestinal OTC drugs market in Americas 2014-2019 ($ million)
Exhibit 19: Gastrointestinal OTC drugs market in EMEA 2014-2019 ($ million)
Exhibit 20: Gastrointestinal OTC drugs market in APAC 2014-2019 ($ million)
Exhibit 21: Key takeaways: Bayer
Exhibit 22: Key takeaways: GlaxoSmithKline
Exhibit 23: Key takeaways: Johnson and Johnson
Exhibit 24: Key takeaways: Perrigo
Exhibit 25: Product portfolio matrix of major vendors
Exhibit 26: Key takeaways: Pfizer
Exhibit 27: Key takeaways: PandG
Exhibit 28: Bayer: business segmentation by revenue 2014
Exhibit 29: Bayer: business segmentation by revenue 2013 and 2014 (US$ billion)
Exhibit 30: Bayer: geographical segmentation by revenue 2014
Exhibit 31: GlaxoSmithKline: business segmentation by revenue 2014
Exhibit 32: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 33: GlaxoSmithKline: geographical segmentation by revenue 2014
Exhibit 34: Johnson and Johnson: business segmentation by revenue 2014
Exhibit 35: Johnson and Johnson: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 36: Johnson and Johnson: geographical segmentation by revenue 2014
Exhibit 37: Perrigo: business segmentation by revenue 2014
Exhibit 38: Perrigo: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 39: Perrigo: geographical segmentation by revenue 2014
Exhibit 40: Pfizer: business segmentation by revenue 2014
Exhibit 41: Pfizer: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 42: Pfizer: geographical segmentation by revenue 2014
Exhibit 43: PandG: business segmentation by revenue 2014
Exhibit 44: PandG: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 45: PandG: geographical segmentation by revenue 2014




























































PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT